Travere Therapeutics's top three insider shareholders as of June 06, 2026 are Eric M Dube (Chief Executive Officer, 432.89K shares), Steve Aselage (Chief Executive Officer, 146.92K shares), Peter Heerma (Chief Commercial Officer, 138.61K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Gary A Lyons | - | 57,500 | 0 | 16 Apr, 2026 |
| Steve Aselage | Chief Executive Officer | 146,919 | 0 | 12 May, 2022 |
| Elizabeth E Reed | Chief Legal Officer And Gc | 105,211 | 0 | 15 Apr, 2026 |
| Brinkley Ruth Williams | - | 25,750 | 0 | 16 May, 2025 |
| Timothy Coughlin | - | 55,500 | 0 | 03 Nov, 2025 |
| Laura Clague | Chief Financial Officer | 35,655 | 0 | 12 May, 2022 |
| Ron Squarer | - | 35,375 | 0 | 16 May, 2025 |
| John A Orwin | - | 35,375 | 0 | 16 May, 2025 |
| Jeffrey A Meckler | - | 87,500 | 0 | 16 May, 2025 |
| Suzanne Louise Bruhn | - | 28,750 | 0 | 16 May, 2025 |
| Noah L. Rosenberg | Chief Medical Officer | 47,614 | 0 | 17 Aug, 2021 |
| Sandra Poole | - | 30,000 | 0 | 16 May, 2025 |
| Roy D. Baynes | - | 37,500 | 0 | 16 Apr, 2026 |
| William E. Rote | Chief Research Officer | 113,987 | 0 | 23 Apr, 2026 |
| Eric M Dube | Chief Executive Officer | 432,886 | 0 | 02 Apr, 2026 |
| Peter Heerma | Chief Commercial Officer | 138,608 | 0 | 15 Apr, 2026 |
| Sandra Calvin | Svp, Chief Accounting Officer | 49,080 | 0 | 03 Feb, 2026 |
| Jula Inrig | Chief Medical Officer | 111,473 | 0 | 15 Apr, 2026 |
| Christopher R. Cline | Chief Financial Officer | 116,899 | 0 | 15 Apr, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 22 Apr, 2026 | William E. Rote | Common Stock | D | 9,100 | $39.09 | 113,987 | D | S |
| 14 Apr, 2026 | Gary A Lyons | Common Stock | A | 8,000 | $16.33 | 65,500 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | A | 8,000 | $17.94 | 45,500 | D | M |
| 14 Apr, 2026 | Sandra Calvin | Common Stock | A | 2,500 | $22.40 | 51,580 | D | M |
| 14 Apr, 2026 | Sandra Calvin | Common Stock | A | 6,250 | $8.93 | 57,830 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | A | 9,000 | $15.43 | 54,500 | D | M |
| 14 Apr, 2026 | Gary A Lyons | Common Stock | D | 8,000 | $41.07 | 57,500 | D | S |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | A | 4,500 | $18.27 | 59,000 | D | M |
| 14 Apr, 2026 | Sandra Calvin | Common Stock | A | 6,500 | $20.46 | 64,330 | D | M |
| 14 Apr, 2026 | Gary A Lyons | Stock option (right to buy) | A | 8,000 | $0.00 | 0 | D | M |
| 14 Apr, 2026 | Sandra Calvin | Common Stock | D | 21,977 | $41.07 | 42,353 | D | S |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | A | 4,500 | $21.38 | 63,500 | D | M |
| 14 Apr, 2026 | Sandra Calvin | Employee stock option (right to buy) | D | 2,500 | $0.00 | 5,000 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | A | 6,750 | $17.11 | 70,250 | D | M |
| 14 Apr, 2026 | Sandra Calvin | Employee stock option (right to buy) | D | 6,250 | $0.00 | 12,500 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | D | 26,000 | $41.07 | 44,250 | D | S |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | D | 6,750 | $42.12 | 37,500 | D | S |
| 14 Apr, 2026 | Sandra Calvin | Employee stock option (right to buy) | D | 6,500 | $0.00 | 19,500 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Stock option (right to buy) | D | 8,000 | $0.00 | 0 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Stock option (right to buy) | D | 9,000 | $0.00 | 0 | D | M |